HealthDay News — One measurement of plasma glycated CD59 (pGCD59) in pregnancy can predict glucose intolerance, according to a study published online in Diabetes Care.
Pamela Ghosh, PhD, from Brigham and Women’s Hospital in Boston, and colleagues conducted a case-control study of 1,000 plasma samples from women receiving standard prenatal care. Five hundred women had a normal glucose challenge test (GCT) for screening of gestational diabetes (GDM), and 500 had a failed GCT and had a subsequent oral glucose tolerance test (control subjects and case patients, respectively).
The researchers found that the median pGCD59 value was 8.5-fold higher in case patients and 10-fold higher in GDM patients compared with controls: 0.33, 2.79, and 3.23, respectively (P <.001). The area under the receiver operating characteristic curve was 0.92. The prevalence of large for gestational age (LGA) was 4.3% and 13.5^ in the lowest and highest quartiles of pGCD59, respectively.
“One pGCD59 measurement during weeks 24 to 28 identifies pregnancy-induced glucose intolerance with high sensitivity and specificity and can potentially identify the risk for LGA,” the authors write.
Two authors disclosed a financial interest in Mellitus, which is developing diagnostic tools for diabetes.
Ghosh P, Luque-Fernandez MA, Vaidya A, et al. Plasma glycated CD59, a novel biomarker for detection of pregnancy-induced glucose intolerance [published online May 3, 2017]. Diabetes Care. doi: 10.2337/dc16-2598